Leveraged Finance Fights Melanoma Raises Record Funds for Cancer Research Initiative
On June 10, 2026, more than 1,100 prominent figures from the leveraged finance, private equity, legal, and investment sectors convened at the Museum of Modern Art for the 15th Annual Leveraged Finance Fights Melanoma (LFFM) event. At this impactful gathering, they collectively raised a staggering $4.3 million for the Melanoma Research Alliance (MRA), the largest nonprofit organization dedicated to funding melanoma research globally.
Since its inception in 2011, LFFM has now amassed nearly $40 million in contributions, primarily aimed at innovating melanoma treatments. Founded by industry leaders Jeff Rowbottom and Brendan Dillon, this grassroots effort has evolved into a critical philanthropic initiative, showcasing the financial community’s ability to significantly enhance cancer research and patient outcomes.
Reflecting on the journey, LFFM Co-Founder Jeff Rowbottom remarked, "Fifteen years ago, we aimed to create something meaningful in the fight against melanoma. The results we've achieved together surpass anything we could have envisioned." Today, the mission continues to inspire funding for research that is making profound effects in melanoma treatment, furthering the fight against all cancer types.
The funds raised each year are strategically allocated to MRA's extensive global research portfolio. This includes pioneering initiatives in next-generation immunotherapies, innovative cell therapies, and artificial intelligence-powered diagnostic tools. The research also prioritizes lesser-known melanoma subtypes, including acral, mucosal, uveal, and pediatric variations, alongside critical studies focusing on brain metastases, a leading cause of mortality in advanced melanoma cases.
Stephanie Kauffman, the incoming CEO of MRA, emphasized the importance of the financial community’s support, stating, "The leaders supporting LFFM understand the transformative power of investing in innovation. For over a decade, they have supported bold scientific ideas and outstanding researchers, facilitating unprecedented progress in the field of melanoma treatment."
Since MRA's establishment in 2007, the organization has directed over $200 million to research activities across 165 institutions worldwide, positively influencing 565 research projects. This vital work has led to the development of 19 FDA-approved therapeutic options, drastically improving survival rates for patients battling advanced melanoma.
The event, which was co-chaired by numerous industry leaders including Clare Bailhe, Brendan Dillon, and others, was backed by a range of top-tier sponsors—among them HPS, Veritas Capital, and Apollo. Such collaborative efforts have played an indispensable role in making significant strides in melanoma research.
With over 112,000 Americans projected to face invasive melanoma diagnoses in 2026, and nearly 8,500 deaths expected this year alone, the urgency for effective treatments and early detection is clear. Notably, melanoma ranks as one of the most prevalent cancers among young adults, with certain demographics—including veterans, active military personnel, and outdoor workers—at heightened risk.
MRA-related research has undeniably shifted the landscape for advanced melanoma. By accelerating discoveries and advancing treatments, the organization has not only raised substantial funding but also invigorated hope for long-term survival among patients. MRA continues to invest in transformative strategies across prevention, diagnosis, treatment, and survivorship, underscoring its mission to eradicate suffering caused by melanoma.
About the Melanoma Research Alliance:
Founded in 2007 by Debra and Leon Black, MRA represents the foremost private, nonprofit entity funding melanoma research. MRA's primary goal is to eliminate the suffering and mortality resulting from melanoma by supporting the most promising scientific innovations. With their model ensuring 100% of public donations go towards research—free from administrative costs—MRA stands as one of the nation's most fiscally efficient nonprofit organizations, furthering its commitment to the cause.
Since its inception in 2011, LFFM has now amassed nearly $40 million in contributions, primarily aimed at innovating melanoma treatments. Founded by industry leaders Jeff Rowbottom and Brendan Dillon, this grassroots effort has evolved into a critical philanthropic initiative, showcasing the financial community’s ability to significantly enhance cancer research and patient outcomes.
Reflecting on the journey, LFFM Co-Founder Jeff Rowbottom remarked, "Fifteen years ago, we aimed to create something meaningful in the fight against melanoma. The results we've achieved together surpass anything we could have envisioned." Today, the mission continues to inspire funding for research that is making profound effects in melanoma treatment, furthering the fight against all cancer types.
The funds raised each year are strategically allocated to MRA's extensive global research portfolio. This includes pioneering initiatives in next-generation immunotherapies, innovative cell therapies, and artificial intelligence-powered diagnostic tools. The research also prioritizes lesser-known melanoma subtypes, including acral, mucosal, uveal, and pediatric variations, alongside critical studies focusing on brain metastases, a leading cause of mortality in advanced melanoma cases.
Stephanie Kauffman, the incoming CEO of MRA, emphasized the importance of the financial community’s support, stating, "The leaders supporting LFFM understand the transformative power of investing in innovation. For over a decade, they have supported bold scientific ideas and outstanding researchers, facilitating unprecedented progress in the field of melanoma treatment."
Since MRA's establishment in 2007, the organization has directed over $200 million to research activities across 165 institutions worldwide, positively influencing 565 research projects. This vital work has led to the development of 19 FDA-approved therapeutic options, drastically improving survival rates for patients battling advanced melanoma.
The event, which was co-chaired by numerous industry leaders including Clare Bailhe, Brendan Dillon, and others, was backed by a range of top-tier sponsors—among them HPS, Veritas Capital, and Apollo. Such collaborative efforts have played an indispensable role in making significant strides in melanoma research.
The Fight Against Melanoma: Statistics That Matter
With over 112,000 Americans projected to face invasive melanoma diagnoses in 2026, and nearly 8,500 deaths expected this year alone, the urgency for effective treatments and early detection is clear. Notably, melanoma ranks as one of the most prevalent cancers among young adults, with certain demographics—including veterans, active military personnel, and outdoor workers—at heightened risk.
MRA-related research has undeniably shifted the landscape for advanced melanoma. By accelerating discoveries and advancing treatments, the organization has not only raised substantial funding but also invigorated hope for long-term survival among patients. MRA continues to invest in transformative strategies across prevention, diagnosis, treatment, and survivorship, underscoring its mission to eradicate suffering caused by melanoma.
About the Melanoma Research Alliance:
Founded in 2007 by Debra and Leon Black, MRA represents the foremost private, nonprofit entity funding melanoma research. MRA's primary goal is to eliminate the suffering and mortality resulting from melanoma by supporting the most promising scientific innovations. With their model ensuring 100% of public donations go towards research—free from administrative costs—MRA stands as one of the nation's most fiscally efficient nonprofit organizations, furthering its commitment to the cause.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.